Projects By Category: CNS and GI
Stay up to date with project updates from the CNS and GI|/projects/category/cns-and-gi category.Latest Industry Projects in CNS and GI
Alemtuzumab (marketed as Campath/MabCampath) is an anti-CD52 monoclonal antibody (MAb) for which Bayer HealthCare holds exclusive global marketing rights. It was licensed in 2001 for the...
> read more
Change Category
Projects In CNS and GI Alphabetically
- Lamictal – Approved Treatment for Epilepsy and Bipolar, United States of America
- Latuda (lurasidone HCl) for the Treatment of Schizophrenia, United States of America
- Lexapro, Other
- Licofelone - Novel Analgesic and Anti-Inflammatory, Other
- Linzess for the Treatment of Irritable Bowel Syndrome with Chronic Idiopathic Constipation, United States of America
- Lurasidone - Treatment for Schizophrenia and Bipolar Disorder, Japan
- LY2140023 – Treatment of Schizophrenia, Other
- Lyrica (Pregabalin) - New Gabapentinoid with Wide, Other
- Sabril (Vigabatrin) - Treatment for Refractory Complex Partial Seizures and IS, United States of America
- Sativex - Investigational Cannabis-Based treatment for Pain and Multiple Sclerosis, Other
- Semagacestat – Gamma Secretase Inhibitor for Alzheimer's Disease, Other
- Seroquel - Treatment for Major Depressive Disorder (MDD), Other
- Silenor (doxepin) for the Treatment of Insomnia, United States of America
- Sycrest (asenapine) - Treatment for Bipolar I Disorder, United States of America